Synthesis and Biological Activity of Enantiomers of Antitumor Irofulven

Journal of Organic Chemistry

Volumn 69, Issue 3, 2004, Pages 619-623

  McMorris, Trevor C ^a   Staake, Michael D ^a   Kelner, Michael J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORGANIC COMPOUNDS; SYNTHESIS (CHEMICAL); TOXICITY;

ENANTIOMERS;

DRUG PRODUCTS;

1 ACETYL 1 (DIAZOACETYL)CYCLOPROPANE; 5 CHLORO 5 METHYL 2 CYCLOPENTENONE; 6 HYDROXYMETHYLACYLFULVENE; ANTINEOPLASTIC AGENT; CYCLOPENTENONE DERIVATIVE; CYCLOPROPANE DERIVATIVE; IROFULVEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN MV 522; CONTROLLED STUDY; CYCLOADDITION; DRUG SYNTHESIS; ENANTIOMER; HUMAN; HUMAN CELL; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY;

ACYLATION; ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; MICE; MOLECULAR STRUCTURE; SESQUITERPENES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0842328956     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo035084j     Document Type: Article

References (17)

1. McMorris, T. C.; Anchel, M. J. Am. Chem. Soc. 1963, 85, 831.
2. McMorris, T. C.; Kelner, M. J.; Wang, W.; Yu, J.; Estes, L. A.; Taetle, R. J. Nat. Prod. 1996, 59, 896.
3. Von Hoff, D. D.; Cox, John, V.; Eder, J. P.; Tempero, M. A.; Eckhardt, G.; Rowinsky, E. K.; Smith, S. L.; Stuart, K. E.; Proper, J.; Campbell, E. R.; MacDonald, J. R. Activity of Irofulven (MGI 114) in Patients With Advanced Pancreatic Cancer Refractory to Gemcitabine. In Proceedings AACR-NCI-EORTC International Conference, Nov 7-10, 2000, Amsterdam; American Association for Cancer Research, Inc.: Philadelphia, PA, 2000; Abstract No. 365.
4. McMorris, T. C.; Hu, Y.; Yu, J.; Kelner, M. J. Chem. Commun. 1997, 315.
5. Brummond, K. M.; Lu, J.; Petersen, J. J. Am. Chem. Soc. 2000, 122, 4915.
6. Rizzo, C. J.; Dujlap, N. K.; Smith, A. B., III J. Org. Chem. 1987, 52, 5280.
7. McMorris, T. C.; Staake, M. D. J. Org. Chem. 2002, 67, 7902.
8. Relative configuration was established by analysis of the racemate corresponding to 7, which was obtained in an earlier experiment from the cycloaddition of diazoketone 6 with (±)-5.
9. Reaction of unprotected 9 with MeMgCl under similar conditions gives the stereoisomeric trans diol in low yield (30%). Cis diol 11 was not detected.
10. Jean-Baptiste, W.; Francois, R. Bull. Soc. Chim. Fr. 1979, 5-6, II-273.
11. Dasanayaki, B. W.; Weedon, A. C. Synthesis 1983, 952.
12. 25D -494.2 (c 2.9 mg/mL, EtOH). This value differs from the value reported in ref 2.
13. McMorris, T. C.; Elayadi, A. N.; Yu, J.; Hu, Y.; Kelner, M. J. Drug Metab. Dispos. 1999, 27 (9), 983.
14. Herzig, M. C.; Arnett, B.; MacDonald, J. R.; Woynarowski, J. M. Biochem. Pharmacol. 1999, 58 (2), 217.
15. Kelner, M. J.; McMorris, T. C.; Taetle, R. J. Natl. Cancer Inst. 1990, 82, 1562.
16. Dick, R. A.; Yu, X.; Kensler, T. Characterization of the Metabolism of the Investigational Anticancer Compound Irofulven and Related Mycotoxins, Illudin S and M, by NADPH-Dependent Alkenal/one Oxidoreductase from the Rat Liver; Proceedings of American Association of Cancer Research, Annual Meeting, Vol. 44, 1st ed., 2003; Abstract 2712.
17. Padwa, A.; Chinn, R. L.; Hornbuckle, S. F.; Zhang, Z. J. J. Org. Chem. 1991, 56, 3271.